XBRANE Biopharma TECHNOLOGY PLATFORMS

Xbrane Biopharma challenges the costly production of biopharmaceuticals with cutting edge technology and know how for production of proteins and microsphere based formulations.

molecule

True generics for injectable controlled release drugs

MICROSPHERES

Xbrane is one of few companies in the world that has the technological know-how to develop and produce generics to drugs with a controlled release formulation based on biodegradable microspheres. Xbrane currently has five generic candidates in its portfolio based on the technology. The most advanced, Spherotide, is expected to become the worlds first generic to a leading GnRH analogue with a controlled release formulation.

HIGH-YIELD PROTEIN PRODUCTION TECHNOLOGY

PROTEIN PRODUCTION PLATFORMS

Xbrane has patented technology and deep know-how in protein production in E.coli. The uniqueness of the technology is the production yield achieved for selective well suited proteins. Xbrane has over time delivered multiple tailor-made protein production platforms to pharmaceutical and biotech companies globally with an average increase of production yield with 8x. Academic studies have demonstrated a 50x higher production  yield with Xbrane technology compared to standard system in E.coli. Needless to say we apply the technology in production of our own biosimilars with very high production yield.